The future is here! PHARMAC have made a decision to fully fund empagliflozin and dulaglutide (pending Medsafe approval) from February 2021 under special authority. What does this mean for type two diabetes management going forward?
Endocrinologist Dr Ryan Paul and RNZCGP Medical Director Dr Bryan Betty discuss the role of these medications in diabetic treatment, guidance on the updated special authority criteria and best practice prescribing.
This webinar will consider a pragmatic approach to use in primary care with a focus on how we can target our vulnerable community to improve health outcomes.
00:00 Intro
01:58 Ryan G Paul presentation
37:33 Bryan Betty presentation
47:58 Audience Q&A
